-
Illnesses produced by vascular diseases are far and away the most common cause of death in the developed world and, amazingly enough, will become the leading cause of death even in the developing world by 2020.1 Identifying individuals at increased risk of coronary artery heart disease (CHD) is critical in preventing CHD and, in 2002, the Adult Treatment Panel III (ATP III)2 reaffirmed its previous position by concluding that low-density lipoprotein cholesterol (LDL-C) would remain the cornerstone of lipid management.
-
This case series and prospective observational study describe propylene glycol toxicity in patients receiving IV benzodiazepines. The authors estimate the incidence of this important but unrecognized complication to be 19%.
-
The FDA has approved the first of a new class of agents, the vaptans. Conivaptan, the first arginine vasopressin receptor antagonist, is approved for the management of serious sodium/water imbalance. It will be marketed by Astellas Pharma US, Inc as Vaprisol®.
-
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency; Prognostic Value of Thyroid Hormone Levels in Acute MI: Just an Epiphenomenon?; Nonsteroidal Anti-inflammatory Drugs and the Risk of Actinic Keratoses and Squamous Cell Cancers of the Skin
-
The 12-lead ECG in the Figure was obtained from a 73-year-old man with dyspnea. What ECG findings do you see that may account for his symptoms?
-
-
Letrozole for Postmenopausal Women with Breast Cancer; Do Antidepressants Increase Risk of Suicide?; Can Viagra Improve Heart Function?; Can Tamoxifen Increase Your Height?; A Dramatic Increase of Clostridium difficile; FDA Actions
-
The first article reports the results of an industry-sponsored clinical trial comparing TDF/ABC/3TC vs EFV/ABC/3TC in treatment-naïve patients. Three hundred forty patients were randomized. Baseline characteristics, including CD4 count and HIV RNA level were similar between the arms.
-
-
Since the fda approval of moxifloxacin in December 1991 for the treatment of community-acquired pneumonia, sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated skin/skin structure infections, its indications for use has been expanded to include the treatment of complicated skin/skin structure infections and complicated intra-abdominal infections.
